News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Scores highest PAT of Rs. 118 crore in FY25
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Subscribe To Our Newsletter & Stay Updated
